Nucl Med Commun. 2022 Jan 1;43(1):73-77. doi: 10.1097/MNM.0000000000001488. ABSTRACT PURPOSE: To determine in a group of patients with progressive metastatic neuroendocrine tumors (PM-NETs) treated with 177Lu-DOTATATE whether a correlation exists between somatostatin receptor (SSTR)-2 expression in various tumors on baseline…
Impact of 18F-DCFPyL PET on Staging and Treatment of Unfavorable Intermediate or High-Risk Prostate Cancer
Radiology. 2022 Sep;304(3):600-608. doi: 10.1148/radiol.211836. Epub 2022 May 24. ABSTRACT Background Data regarding 2-(3-{1-carboxy-5-fluoro-pyridine 3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) PET in primary staging of prostate cancer (PCa) are limited. Purpose To compare the performance of 18F-DCFPyL PET/CT or PET/MRI (PET) with bone…
Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!